The Patent Finder
KT

Keros Therapeutics, Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

18 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2037. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2037
Next term end
13
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 8, 2027
    The maintenance fee for Nucleic Acid Molecules Encoding Activin Receptor Type Iia Variants (US 11,717,558) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 1 fee due Jul 30, 2027
    The maintenance fee for Activin Receptor Type Iib Variants and Methods of Use Thereof (US 11,884,715) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for GDNF Fusion Polypeptides and Methods of Use Thereof (US 11,912,750) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

What they patent

The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,013,785Activin Receptor Type Iia Variants and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,912,750GDNF Fusion Polypeptides and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,350,313Activin Receptor Type Iia Variants and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,404,313GDNF Fusion Polypeptides and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,582,700Activin Receptor Type Iia Variants and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,090,361Activin Receptor Type Iia Variants and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,717,558Nucleic Acid Molecules Encoding Activin Receptor Type Iia Variants
In force
 · High confidence
In forceHigh confidence
US 12,269,858Activin Receptor Type Iib Variants and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,484,573Activin Receptor Type Iia Variants and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,884,715Activin Receptor Type Iib Variants and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 20 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited